Latest News and Press Releases

Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma...

Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés...

MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...

Marseille, France, 17 sept. 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd'hui qu’AstraZeneca (LSE/STO/Nasdaq : AZN)...

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...

Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- Les premières données cliniques de TELLOMAK ont établi un taux de réponse global encourageant de 35% avec lacutamab, ainsi qu’une amélioration au niveau...

Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with...

First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2New...

Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- RAPPORT FINANCIER SEMESTRIEL30 JUIN 2021 INNATE PHARMA S.A.Société anonyme à Directoire et Conseil de surveillanceau capital social de 3 952 095,85...